Mariana A. Callero

Mariana A. Callero

Auto-generated profile, based on publicly available information

Mariana A. Callero

Universidad de Buenos Aires, Instituto de Oncología "Ángel H. Roffo", Área Investigaciones, Ciudad de Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Cancer Letters
Verified
Journal Article
Closed access
EBEileen Brantley
Eileen Brantley
MCMariana A. Callero
Mariana A. Callero
DBDamian E. Berardi
Damian E. Berardi
PCPetreena Campbell
Petreena Campbell
LRLeah Rowland
Leah Rowland
USUbaldo Soto
Ubaldo Soto

12 June 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
GLGabriela A. Luzzani
Gabriela A. Luzzani
MCMariana A. Callero
Mariana A. Callero
AKAnchala I. Kuruppu
Anchala I. Kuruppu
VTValentina Trapani
Valentina Trapani
CFCarolina Flumian
Carolina Flumian
ALAndrea Loaiza-Perez
Andrea Loaiza-Perez

4 January 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ASAldana Sólimo
Aldana Sólimo
MSMaria Cristina Soraires Santacruz
Maria Cristina Soraires Santacruz
APAndrea I. Loaiza Perez
Andrea I. Loaiza Perez
EJElisa Bal de Kier Joffé
Elisa Bal de Kier Joffé
LFLiliana M. Finkielsztein
Liliana M. Finkielsztein
MCMariana A. Callero
Mariana A. Callero

27 April 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MCMariana A. Callero
Mariana A. Callero
CRCristina E. Rodriguez
Cristina E. Rodriguez
ASAldana Sólimo
Aldana Sólimo
EJElisa Bal de Kier Joffé
Elisa Bal de Kier Joffé
ALAndrea Loaiza-Perez
Andrea Loaiza-Perez

1 October 2020 in Heliyon
Verified
Journal Article
Open access
ASA.M. Sólimo
A.M. Sólimo
MSM.C. Soraires Santacruz
M.C. Soraires Santacruz
SVS. Vanzulli
S. Vanzulli
OCO. Coggiola
O. Coggiola
EJE. Bal de Kier Joffé
E. Bal de Kier Joffé
MCM.A. Callero
M.A. Callero
Advanced triple negative breast cancer (ATNBC) is defined by a lack of expression of hormones receptors as well as HER2/neu and its high probability of visceral metastasis. This pathology is associated with a poor prognosis. Previously, we found that T2, an N4-arylsubstituted thiosemicarbazone (N4-TSC), had cytotoxic effect on human breast cancer cells lines. Hence, in this study, we investigated the anti-metastasic action of T2 on ATNBC. In order to deepen T2 action mode on ATNBC, we first confirmed T2 cytotoxicity on a panel of TNBC cells and then continued studying T2 effects in vitro an in vivo on the syngeneic 4T1 mouse model. We found that T2 had a cytotoxic effect comparable to chemotherapeutics used in present treatment schemes for ATNBC. T2 treatment not only induced apoptosis, but it also down-modulated 4T1 invasive and metastatic-associated capacities, such as clonogenicity, migration and metallo-proteases activity. Moreover, this agent reduced the number of 4T1 cancer stem cells. Finally, T2 treatment induced a more differentiated cell phenotype and the overexpression of the metastasis suppressor gene NDRG-1. In vivo assays showed that T2 reduced tumor burden, down modulated local tumor invasion and significantly reduced the number of lung metastases in the 4T1 advanced TNBC murine model, while the compound did not exhibit intolerable toxicity. This study provided evidence that T2 not only exerted an anti-tumor activity but it also showed anti-invasive and anti-metastatic actions on ATNBC in vivo and in vitro, suggesting that T2 could be considered as a promising therapy that deserves further analysis.

9 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAldana M Sólimo
Aldana M Sólimo
MSMarianela Sciacca
Marianela Sciacca
FCFlorencia Cascardo
Florencia Cascardo
LFLiliana M. Finkielsztein
Liliana M. Finkielsztein
AEAna Maria Eijan
Ana Maria Eijan
MCMariana A Callero
Mariana A Callero
T2, an N4-aryl-substituted thiosemicarbazone, has previously been shown to exert cytotoxic and anti-invasive effects in triple-negative breast cancer (TNBC) and to increase expression of the metastasis suppressor N-myc downstream-regulated gene 1 (NDRG1). Given the role of NDRG1 in regulating epithelial–mesenchymal transition (EMT) and WNT/β-catenin signaling, we investigated the contribution of this pathway to the anti-invasive activity of T2. The effects of T2 on WNT/β-catenin signaling and associated microRNAs (miR-182-5p and miR-200c) were evaluated in 4T1 cells. In vivo activity was assessed using a fully immunocompetent intraductal 4T1 mouse model that recapitulates the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). Tumor progression, invasion, NDRG1 expression, and WNT/β-catenin pathway components were analyzed. T2 reduced WNT/β-catenin signaling and modulated the expression of miR-182-5p and miR-200c in vitro. In the MIND model, T2 decreased the frequency of invasive lesions and reduced β-catenin, ZEB1, and c-Myc expression while increasing NDRG1 levels. β-catenin localization differed between lesion types, showing predominantly membrane-associated staining in DCIS lesions and a diffuse cytoplasmic distribution in invasive foci. These findings identify WNT/β-catenin signaling and NDRG1-associated pathways as potential mediators of the anti-invasive effects of T2 in TNBC. The reduction in invasive progression observed in the MIND model supports further investigation of this compound in preclinical models of TNBC.